Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 45 for your search:
Drug:
tamoxifen citrate
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GCO# 08-1373
, NCT00900744
2.
Second-Line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
not specified
Sponsor:
Other
Protocol IDs:
N07MAN
, Eudract 2007-007030-20, NCT00684216
3.
Phase III Randomized Study of Ovarian Function Suppression in Combination With Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women With Endocrine-Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Premenopausal
Sponsor:
NCI
Protocol IDs:
IBCSG-2402
, BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13
4.
Phase III Randomized Study of Triptorelin and Exemestane Versus Triptorelin and Tamoxifen in Premenopausal Women With Endocrine-Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Premenopausal
Sponsor:
NCI
Protocol IDs:
IBCSG-25-02
, BIG-3-02, NABCI-IBCSG-25-02, EU-20347, NCT00066703, EUDRACT-2004-000168-28
5.
Phase III Randomized Study of Adjuvant Tamoxifen Versus Anastrozole in Postmenopausal Women With Ductal Carcinoma In Situ
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
40 to 70
Sponsor:
Other
Protocol IDs:
CRUK-IBIS-II-DCIS
, EU-20226, BIG-5-02, NCT00072462, IBCSG-31-03-DCIS, ISRCTN31488319
6.
Luteal v. Follicular Phase Surgical Oophorectomy & Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor + Br. CA
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
OSU-0476
, NCT00293540
7.
Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
ECOG-PACCT-1
, SWOG-ECOG-PACCT-1, CALGB-ECOG-PACCT-1, NCCTG-ECOG-PACCT-1, NSABP-ECOG-PACCT-1, ACOSOG-ECOG-PACCT-1, CAN-NCIC-MAC12, PACCT-1, NCT00310180, TAILORx
8.
Phase III Randomized Study of 70-Gene Signature Versus Clinical Assessment in Selecting Women With Node-Negative Breast Cancer for Adjuvant Chemotherapy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
EORTC-10041
, EUDRACT-2005-002625-31, BIG-3-04, NOVARTIS-EORTC-10041, ROCHE-EORTC-10041, SANOFI-AVENTIS-EORTC-10041, NCT00433589
9.
HOBOE: A Study of Hormonal Adjuvant Treatment Effect on Bone Mineral Density in Early Breast Cancer Patients
Phase:
Phase III
Type:
Supportive care
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
HOBOE
, NCT00412022
10.
Phase III Randomized Study of Adjuvant Therapy Comprising Tamoxifen Citrate Followed By Either Anastrozole, Letrozole, or Exemestane Versus Anastrozole, Letrozole, or Exemestane Alone in Postmenopausal Women With Resected Endocrine-Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
GIM-3-FATA
, GIM3-FATA, EUDRACT-2006-004018-42, EU-20764, NCT00541086
11.
Phase III Randomized Study of Tamoxifen Citrate or Letrozole With Versus Without Bevacizumab in Women With Hormone Receptor-Positive Stage IIIB-IV Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-40503
, CALGB 40503, NCT00601900
12.
Phase III Randomized Study of Two Different Regimens of Adjuvant Chemotherapy and Trastuzumab (Herceptin®) in Women With HER2-Positive Stage I-IIIA Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
AOUMODENA-SHORT-HER
, EudraCT 2007-004326-25, EUDRACT-2007-004326-25, EU-20825, NCT00629278
13.
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
20 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
D539BC00001
, NCT00605267
14.
Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women
Phase:
Phase III
Type:
Prevention
Status:
Active
Age:
30 to 75
Sponsor:
Other
Protocol IDs:
GD-10-08
, NCT00808522
15.
Phase III Randomized Study of Adjuvant Endocrine Therapy Comprising Letrozole, Anastrazole, or Exemestane Versus Tamoxifen Citrate in Postmenopausal Women With Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
COL-MNEMOSYNE
, MNEMOSYNE, 2007-12, INCA-RECF0899, EUDRACT-2008-003620-32, NCT00893061
16.
Phase III Randomized Study of Adjuvant Therapy Comprising Tamoxifen Citrate Alone Versus Ovarian Function Suppression and Tamoxifen Citrate Versus Ovarian Function Suppression and Exemestane in Premenopausal Women Who Have Undergone Surgery for Hormone Receptor-Positive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Premenopausal
Sponsor:
Other
Protocol IDs:
ICORG-06-02
, ICORG 06-02, IBCSG 24-02, SOFT, BIG 2-02, EUDRACT-2004-000166-13, EU-20916, NCT00917969
17.
Phase III Randomized Study of Neoadjuvant Letrozole Versus Tamoxifen Citrate in Older Postmenopausal Women With Estrogen Receptor-Positive Breast Adenocarcinoma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
65 and over
Sponsor:
Other
Protocol IDs:
CLCC-LETROTAM
, LETROTAM, VA 2007/09, INCA-RECF0916, EUDRACT-2007-000900-34, NCT00949598
18.
Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
349
, NCT00896155
19.
Phase III Study of Effect of Tamoxifen Citrate Dose on Level of Active Metabolites in Patients With Hormone-Sensitive Breast Cancer
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
CHUV-CEPO-TM
, CHUV-CEPO-Tamoxifen metabolism, EU-20973, NCT00963209
20.
Phase II Study of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-05-C-0137
, NCT00112762
21.
Phase II Study of Lapatinib and Tamoxifen in Patients With Tamoxifen-Resistant Locally Advanced or Metastatic Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
WSU-C-2876
, 6724, NCI-6724, NCT00118157
22.
Phase II Study of CA 125 Doubling Time in Patients With Relapsed Advanced Ovarian Carcinoma, Fallopian Tube Carcinoma, or Primary Peritoneal Carcinoma Receiving Tamoxifen Citrate
Phase:
Phase II
Type:
Diagnostic, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
MTVERNHOSP-CA125
, EU-205113, NCRN-1509, MREC-EC2003-62, NCT00305838
23.
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
MCC-14662
, NCT00365599
24.
Phase II Pilot Study of Radiotherapy With Concurrent and Adjuvant Temozolomide, Tamoxifen Citrate, and Carboplatin in Patients With Malignant Gliomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
POHA-0601
, 06-01, NCT00492687
25.
Phase II Pilot Study of Adjuvant Sorafenib Tosylate, Tamoxifen Citrate, and Cisplatin in Patients With High-Risk Stage III Malignant Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
POHA-0602
, 06-02, NCT00492505
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
